Primary Sclerosing Cholangitis-Associated Pouchitis: A Distinct Clinical Phenotype

Area of Science:

• Gastroenterology
• Inflammatory Bowel Disease
• Surgical Outcomes

Background:

• Primary sclerosing cholangitis (PSC) patients often require ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC) or dysplasia.
• Pouchitis is a common complication post-IPAA, with higher incidence in PSC patients, potentially increasing morbidity.

Purpose of the Study:

• To compare the clinical characteristics and treatment outcomes of pouchitis in patients with PSC versus a matched non-PSC cohort.
• To identify unique features of pouchitis associated with PSC.

Main Methods:

• Retrospective analysis of patients with PSC who underwent IPAA and developed pouchitis (PSC-pouchitis).
• A matched cohort of non-PSC patients with UC who developed pouchitis (UC-pouchitis) was created for comparison.
• Demographic, clinical, endoscopic, histologic, and treatment data were collected and analyzed.

Main Results:

• PSC-pouchitis patients were more likely to have undergone IPAA for medically-refractory disease (53.9%) than UC-pouchitis patients (88.7%).
• PSC-pouchitis was associated with higher rates of chronic pouchitis (68.1% vs 34.1%), moderate-to-severe inflammation (54.9% vs 32.4%), and prepouch ileitis (34.1% vs 11.5%).
• PSC-pouchitis showed increased rates of chronic antibiotic-dependent (50.6% vs 25.8%) and antibiotic-refractory pouchitis (17.6% vs 7.7%), with similar responses to thiopurines, anti-TNF, and newer biologics.

Conclusions:

• Pouchitis in PSC patients exhibits a distinct clinical phenotype.
• This phenotype includes increased risk of chronic pouchitis, severe inflammation, and prepouch ileitis.
• PSC-associated pouchitis demonstrates reduced response to conventional antimicrobial therapies.